Cytokinetics Set to Join Russell Global Index
(Thomson Reuters ONE) -
South San Francisco, CA June 17, 2013 - Cytokinetics Incorporated (NASDAQ:CYTK)
announced today that it is set to join the Russell Global Index when Russell
Investments reconstitutes its comprehensive set of U.S. and global equity
indexes on June 28, 2013, according to a preliminary list of additions posted
June 14, 2013 on www.russell.com/indexes.
Membership in the Russell Global Index, which remains in place for one year,
means automatic inclusion in the appropriate large-cap, small-cap, all-cap
indexes as well as the applicable style, sector and country indexes. Russell
determines membership for its equity indexes primarily by objective, market-
capitalization rankings and style attributes. Russell indexes are widely used
by investment managers and institutional investors for index funds and as
benchmarks for both passive and active investment strategies. Approximately $4.1
trillion in assets currently are benchmarked to them.
About Cytokinetics
Cytokinetics is a clinical-stage biopharmaceutical company focused on the
discovery and development of novel small molecule therapeutics that modulate
muscle function for the potential treatment of serious diseases and medical
conditions. Cytokinetics' lead drug candidate from its cardiac muscle
contractility program, omecamtiv mecarbil, is in Phase II clinical development
for the potential treatment of heart failure. Amgen Inc. holds an exclusive
license worldwide to develop and commercialize omecamtiv mecarbil and related
compounds, subject to Cytokinetics' specified development and commercialization
participation rights. Cytokinetics is independently developing tirasemtiv and
CK-2127107, both fast skeletal muscle activators, as potential treatments for
diseases and medical conditions associated with aging, muscle wasting or
neuromuscular dysfunction. Tirasemtiv is currently the subject of a Phase II
clinical trials program and has been granted orphan drug designation and fast
track status by the U.S. Food and Drug Administration and orphan medicinal
product designation by the European Medicines Agency for the potential treatment
of amyotrophic lateral sclerosis, a debilitating disease of neuromuscular
impairment in which treatment with tirasemtiv produced potentially clinically
relevant pharmacodynamic effects in Phase II trials. All of these drug
candidates have arisen from Cytokinetics' muscle biology focused research
activities and are directed towards the cytoskeleton. The cytoskeleton is a
complex biological infrastructure that plays a fundamental role within every
human cell. Additional information about Cytokinetics can be obtained at
www.cytokinetics.com.
Forward-Looking Statement: Cytokinetics
This press release contains forward-looking statements for purposes of the
Private Securities Litigation Reform Act of 1995 (the "Act"). Cytokinetics
disclaims any intent or obligation to update these forward-looking statements,
and claims the protection of the Act's safe harbor for forward-looking
statements. Examples of such statements include, but are not limited to,
statements relating to Cytokinetics' inclusion in the Russell Global Index and
the properties and potential benefits of Cytokinetics' drug candidates and
potential drug candidates. Such statements are based on management's current
expectations, but actual results may differ materially due to various risks and
uncertainties, including, but not limited to, potential difficulties or delays
in the development, testing, regulatory approval and production of Cytokinetics'
drug candidates and potential drug candidates that could slow or prevent
clinical development or product approval, including risks that current and past
results of clinical trials or preclinical studies may not be indicative of
future clinical trials results and that Cytokinetics' drug candidates and
potential drug candidates may have unexpected adverse side effects or inadequate
therapeutic efficacy. For further information regarding these and other risks
related to Cytokinetics' business, investors should consult Cytokinetics'
filings with the Securities and Exchange Commission.
Contact:
Cytokinetics, Inc.
Joanna L. Goldstein (Investors & Media)
(650) 624-3000
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Cytokinetics, Inc. via Thomson Reuters ONE
[HUG#1709786]
Unternehmensinformation / Kurzprofil:
Datum: 17.06.2013 - 07:11 Uhr
Sprache: Deutsch
News-ID 270068
Anzahl Zeichen: 5431
contact information:
Town:
SOUTH SAN FRANCISCO
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 248 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Cytokinetics Set to Join Russell Global Index"
steht unter der journalistisch-redaktionellen Verantwortung von
Cytokinetics, Inc. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
